Increased Mild Vaccine-Related Side Effects and Higher Specific Antibody Titers in Health Care Workers with Previous SARS-CoV-2 Infection after the mRNA BNT162b2 Vaccine
Background: to evaluate whether prior SARS-CoV-2 infection affects side effects and specific antibody production after vaccination with BNT162b2. Methods: We included 1106 health care workers vaccinated with BNT162b2. We assessed whether prior SARS-CoV-2 infection affects the number and type of side...
| Main Authors: | , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-08-01
|
| Series: | Vaccines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2076-393X/10/8/1238 |
| _version_ | 1827617473842642944 |
|---|---|
| author | Ludovica Ferrari Mirko Compagno Laura Campogiani Elisabetta Teti Tiziana Mulas Davide Checchi Grazia Alessio Federica Caldara Luigi Coppola Giuseppe De Simone Laura Ceccarelli Ilaria Spalliera Pietro Vitale Sandro Grelli Massimo Andreoni Loredana Sarmati Marco Iannetta |
| author_facet | Ludovica Ferrari Mirko Compagno Laura Campogiani Elisabetta Teti Tiziana Mulas Davide Checchi Grazia Alessio Federica Caldara Luigi Coppola Giuseppe De Simone Laura Ceccarelli Ilaria Spalliera Pietro Vitale Sandro Grelli Massimo Andreoni Loredana Sarmati Marco Iannetta |
| author_sort | Ludovica Ferrari |
| collection | DOAJ |
| description | Background: to evaluate whether prior SARS-CoV-2 infection affects side effects and specific antibody production after vaccination with BNT162b2. Methods: We included 1106 health care workers vaccinated with BNT162b2. We assessed whether prior SARS-CoV-2 infection affects the number and type of side effects and performed a nested case–control analysis comparing plasma levels of specific IgG titers between SARS-CoV-2-naïve and previously infected subjects after the first and the second vaccine doses. Results: After the first dose, SARS-CoV-2-naïve subjects experienced side effects more often than SARS-CoV-2 naïve subjects. Individuals with prior SARS-CoV-2 infection more often reported pain at the injection site, weakness, and fever than SARS-CoV-2-naïve subjects. After the second dose, the frequency of side effects was similar in the two groups. All subjects with prior SARS-CoV-2 infection developed either a high (>100 AU/mL) or intermediate (10–100 AU/mL) antibody titer. Among SARS-CoV-2-naïve subjects, the majority developed an intermediate titer. After the second dose, a high (>2000 AU/mL) antibody titer was more common among subjects with prior SARS-CoV-2 infection. Conclusions: vaccine-related side effects and a higher anti-SARS-CoV-2-RBD IgG titer were more common in subjects with previous infection than in SARS-CoV-2-naïve after the first, but not after the second dose of the BNT162b2 vaccine. |
| first_indexed | 2024-03-09T09:47:31Z |
| format | Article |
| id | doaj.art-1095e62963ea44edbe361b2823a9f243 |
| institution | Directory Open Access Journal |
| issn | 2076-393X |
| language | English |
| last_indexed | 2024-03-09T09:47:31Z |
| publishDate | 2022-08-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Vaccines |
| spelling | doaj.art-1095e62963ea44edbe361b2823a9f2432023-12-02T00:25:11ZengMDPI AGVaccines2076-393X2022-08-01108123810.3390/vaccines10081238Increased Mild Vaccine-Related Side Effects and Higher Specific Antibody Titers in Health Care Workers with Previous SARS-CoV-2 Infection after the mRNA BNT162b2 VaccineLudovica Ferrari0Mirko Compagno1Laura Campogiani2Elisabetta Teti3Tiziana Mulas4Davide Checchi5Grazia Alessio6Federica Caldara7Luigi Coppola8Giuseppe De Simone9Laura Ceccarelli10Ilaria Spalliera11Pietro Vitale12Sandro Grelli13Massimo Andreoni14Loredana Sarmati15Marco Iannetta16Infectious Diseases Clinic, Policlinic of Tor Vergata, 00133 Rome, ItalyInfectious Diseases Clinic, Policlinic of Tor Vergata, 00133 Rome, ItalyInfectious Diseases Clinic, Policlinic of Tor Vergata, 00133 Rome, ItalyInfectious Diseases Clinic, Policlinic of Tor Vergata, 00133 Rome, ItalyInfectious Diseases Clinic, Policlinic of Tor Vergata, 00133 Rome, ItalyInfectious Diseases Clinic, Policlinic of Tor Vergata, 00133 Rome, ItalyInfectious Diseases Clinic, Policlinic of Tor Vergata, 00133 Rome, ItalyInfectious Diseases Clinic, Policlinic of Tor Vergata, 00133 Rome, ItalyInfectious Diseases Clinic, Policlinic of Tor Vergata, 00133 Rome, ItalyInfectious Diseases Clinic, Policlinic of Tor Vergata, 00133 Rome, ItalyInfectious Diseases Clinic, Policlinic of Tor Vergata, 00133 Rome, ItalyInfectious Diseases Clinic, Policlinic of Tor Vergata, 00133 Rome, ItalyInfectious Diseases Clinic, Policlinic of Tor Vergata, 00133 Rome, ItalyDepartment of Experimental Medicine, University of Rome Tor Vergata, 00133 Rome, ItalyDepartment of Systems Medicine, University of Rome Tor Vergata, Via Montpellier 1, 00133 Rome, ItalyDepartment of Systems Medicine, University of Rome Tor Vergata, Via Montpellier 1, 00133 Rome, ItalyDepartment of Systems Medicine, University of Rome Tor Vergata, Via Montpellier 1, 00133 Rome, ItalyBackground: to evaluate whether prior SARS-CoV-2 infection affects side effects and specific antibody production after vaccination with BNT162b2. Methods: We included 1106 health care workers vaccinated with BNT162b2. We assessed whether prior SARS-CoV-2 infection affects the number and type of side effects and performed a nested case–control analysis comparing plasma levels of specific IgG titers between SARS-CoV-2-naïve and previously infected subjects after the first and the second vaccine doses. Results: After the first dose, SARS-CoV-2-naïve subjects experienced side effects more often than SARS-CoV-2 naïve subjects. Individuals with prior SARS-CoV-2 infection more often reported pain at the injection site, weakness, and fever than SARS-CoV-2-naïve subjects. After the second dose, the frequency of side effects was similar in the two groups. All subjects with prior SARS-CoV-2 infection developed either a high (>100 AU/mL) or intermediate (10–100 AU/mL) antibody titer. Among SARS-CoV-2-naïve subjects, the majority developed an intermediate titer. After the second dose, a high (>2000 AU/mL) antibody titer was more common among subjects with prior SARS-CoV-2 infection. Conclusions: vaccine-related side effects and a higher anti-SARS-CoV-2-RBD IgG titer were more common in subjects with previous infection than in SARS-CoV-2-naïve after the first, but not after the second dose of the BNT162b2 vaccine.https://www.mdpi.com/2076-393X/10/8/1238vaccinesSARS-CoV-2COVID-19healthcare workersBNT162b2side effects |
| spellingShingle | Ludovica Ferrari Mirko Compagno Laura Campogiani Elisabetta Teti Tiziana Mulas Davide Checchi Grazia Alessio Federica Caldara Luigi Coppola Giuseppe De Simone Laura Ceccarelli Ilaria Spalliera Pietro Vitale Sandro Grelli Massimo Andreoni Loredana Sarmati Marco Iannetta Increased Mild Vaccine-Related Side Effects and Higher Specific Antibody Titers in Health Care Workers with Previous SARS-CoV-2 Infection after the mRNA BNT162b2 Vaccine Vaccines vaccines SARS-CoV-2 COVID-19 healthcare workers BNT162b2 side effects |
| title | Increased Mild Vaccine-Related Side Effects and Higher Specific Antibody Titers in Health Care Workers with Previous SARS-CoV-2 Infection after the mRNA BNT162b2 Vaccine |
| title_full | Increased Mild Vaccine-Related Side Effects and Higher Specific Antibody Titers in Health Care Workers with Previous SARS-CoV-2 Infection after the mRNA BNT162b2 Vaccine |
| title_fullStr | Increased Mild Vaccine-Related Side Effects and Higher Specific Antibody Titers in Health Care Workers with Previous SARS-CoV-2 Infection after the mRNA BNT162b2 Vaccine |
| title_full_unstemmed | Increased Mild Vaccine-Related Side Effects and Higher Specific Antibody Titers in Health Care Workers with Previous SARS-CoV-2 Infection after the mRNA BNT162b2 Vaccine |
| title_short | Increased Mild Vaccine-Related Side Effects and Higher Specific Antibody Titers in Health Care Workers with Previous SARS-CoV-2 Infection after the mRNA BNT162b2 Vaccine |
| title_sort | increased mild vaccine related side effects and higher specific antibody titers in health care workers with previous sars cov 2 infection after the mrna bnt162b2 vaccine |
| topic | vaccines SARS-CoV-2 COVID-19 healthcare workers BNT162b2 side effects |
| url | https://www.mdpi.com/2076-393X/10/8/1238 |
| work_keys_str_mv | AT ludovicaferrari increasedmildvaccinerelatedsideeffectsandhigherspecificantibodytitersinhealthcareworkerswithprevioussarscov2infectionafterthemrnabnt162b2vaccine AT mirkocompagno increasedmildvaccinerelatedsideeffectsandhigherspecificantibodytitersinhealthcareworkerswithprevioussarscov2infectionafterthemrnabnt162b2vaccine AT lauracampogiani increasedmildvaccinerelatedsideeffectsandhigherspecificantibodytitersinhealthcareworkerswithprevioussarscov2infectionafterthemrnabnt162b2vaccine AT elisabettateti increasedmildvaccinerelatedsideeffectsandhigherspecificantibodytitersinhealthcareworkerswithprevioussarscov2infectionafterthemrnabnt162b2vaccine AT tizianamulas increasedmildvaccinerelatedsideeffectsandhigherspecificantibodytitersinhealthcareworkerswithprevioussarscov2infectionafterthemrnabnt162b2vaccine AT davidechecchi increasedmildvaccinerelatedsideeffectsandhigherspecificantibodytitersinhealthcareworkerswithprevioussarscov2infectionafterthemrnabnt162b2vaccine AT graziaalessio increasedmildvaccinerelatedsideeffectsandhigherspecificantibodytitersinhealthcareworkerswithprevioussarscov2infectionafterthemrnabnt162b2vaccine AT federicacaldara increasedmildvaccinerelatedsideeffectsandhigherspecificantibodytitersinhealthcareworkerswithprevioussarscov2infectionafterthemrnabnt162b2vaccine AT luigicoppola increasedmildvaccinerelatedsideeffectsandhigherspecificantibodytitersinhealthcareworkerswithprevioussarscov2infectionafterthemrnabnt162b2vaccine AT giuseppedesimone increasedmildvaccinerelatedsideeffectsandhigherspecificantibodytitersinhealthcareworkerswithprevioussarscov2infectionafterthemrnabnt162b2vaccine AT lauraceccarelli increasedmildvaccinerelatedsideeffectsandhigherspecificantibodytitersinhealthcareworkerswithprevioussarscov2infectionafterthemrnabnt162b2vaccine AT ilariaspalliera increasedmildvaccinerelatedsideeffectsandhigherspecificantibodytitersinhealthcareworkerswithprevioussarscov2infectionafterthemrnabnt162b2vaccine AT pietrovitale increasedmildvaccinerelatedsideeffectsandhigherspecificantibodytitersinhealthcareworkerswithprevioussarscov2infectionafterthemrnabnt162b2vaccine AT sandrogrelli increasedmildvaccinerelatedsideeffectsandhigherspecificantibodytitersinhealthcareworkerswithprevioussarscov2infectionafterthemrnabnt162b2vaccine AT massimoandreoni increasedmildvaccinerelatedsideeffectsandhigherspecificantibodytitersinhealthcareworkerswithprevioussarscov2infectionafterthemrnabnt162b2vaccine AT loredanasarmati increasedmildvaccinerelatedsideeffectsandhigherspecificantibodytitersinhealthcareworkerswithprevioussarscov2infectionafterthemrnabnt162b2vaccine AT marcoiannetta increasedmildvaccinerelatedsideeffectsandhigherspecificantibodytitersinhealthcareworkerswithprevioussarscov2infectionafterthemrnabnt162b2vaccine |